Open AccessA Combination of the Aerosolized PPAR-γ Agonist Pioglitazone and a Synthetic Surfactant Protein B Peptide Mimic Prevents Hyperoxia-Induced Neonatal Lung Injury in Rats
Author(s) -
Reiko Sakurai,
Cindy Lee,
Humphrey Shen,
Alan J. Waring,
Frans J. Walther,
Virender K. Rehan
Publication year - 2018
Publication title -
neonatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.399
H-Index - 84
eISSN - 1661-7819
pISSN - 1661-7800
DOI - 10.1159/000486188
Subject(s) - bronchopulmonary dysplasia , hyperoxia , lung , pioglitazone , medicine , bronchoalveolar lavage , endocrinology , pharmacology , biology , diabetes mellitus , gestational age , pregnancy , genetics , type 2 diabetes
Despite improvements in perinatal care, bronchopulmonary dysplasia (BPD) in extremely premature infants has not decreased. Postnatal surfactant therapy provides symptomatic relief from respiratory distress syndrome, but does not translate into a reduction in BPD. Therefore, the search for effective interventions to prevent BPD continues.